St Georges University of London, Institute of Infection and Immunity, London, UK.
St Georges University Hospitals NHS Foundation Trust, Thomas Addison Unit, London, UK.
Free Radic Biol Med. 2020 Dec;161:283-289. doi: 10.1016/j.freeradbiomed.2020.10.005. Epub 2020 Oct 9.
The role of antioxidant status on microvascular blood flow and glomerular filtration (eGFR) in patients with type 2 diabetes and hypertension whose risk of progressive renal disease varies by ethnicity is unknown.
Adult, non-Caucasian (n = 101) and Caucasian (n = 69) patients with type 2 diabetes, hypertension and/or microalbuminuria and an eGFR > 45 mL/min/1.73 m were randomised to receive 400 IU vitamin E and/or 20 μg selenium daily or matching placebo. eGFR (CKD-EPI) was measured at baseline, 3,6 and 12 months and renal blood flow by contrast-enhanced ultrasonography in a sub-group (n = 9) at baseline and 3 months by assessing the area under the time intensity curve (TIC). Circulating glutathione peroxidase 3 (GPx-3) activity was measured as a biomarker of oxidative defence status.
The time to change in eGFR was shortest with combined vitamin E and selenium than usual care (5.6 [4.0-7.0] vs 8.9 [6.8-10.9 months]; p = 0.006). Area under the TIC was reduced compared to baseline (38.52 [22.41-90.49] vs 123 [86.98-367.03]dB.s; P ≤ 0.05 and 347 [175.88-654.92] vs 928.03 [448.45-1683]dB.s; P ≤ 0.05, respectively] at 3 months suggesting an increase in rate of perfusion. The proportional change in eGFR at 12 months was greater in the group whose GPx-3 activity was above, compared with those below the cohort median (360 U/L) in the non-Caucasian and the Caucasian groups (19.1(12.5-25.7] % vs 6.5[-3.5 to 16.5] % and 12.8 [0.7 to 24] % vs 0.2 [-6.1 to 6.5] %).
In these patients with type 2 diabetes and early CKD, antioxidant treatment derepresses renal blood flow and a rise in eGFR correlated directly with GPx-3 activity.
Diabetes mellitus is the world's leading cause of end-stage renal disease which has a predilection for black and minor ethnic groups compared with Caucasians. The differences in risk despite the benefits of conventional care may be related to oxidative stress. We found that glomerular filtration and renal blood flow is suppressed when renal function is preserved in high-risk patients with type 2 diabetes. Conventional care supplemented with selenium - the co-factor for glutathione peroxidase-3 (GPx-3) - improves renal perfusion and increase glomerular filtration according to host antioxidant defence determined by GPx-3 activity. Circulating GPx-3 activity warrants further investigation as a novel biomarker of reversible haemodynamic changes in early diabetic kidney disease to better enable targeting of renoprotective strategies.
抗氧化状态对 2 型糖尿病和高血压患者的微血管血流和肾小球滤过率(eGFR)的作用因种族而异,这些患者的肾脏疾病进展风险各不相同。
将非裔(n=101)和白种人(n=69)成年、非白种人(n=101)和白种人(n=69)2 型糖尿病、高血压和/或微量白蛋白尿且 eGFR>45 mL/min/1.73 m 的患者随机分为接受 400 IU 维生素 E 和/或 20 μg 硒或匹配安慰剂治疗。在基线和 3、6 和 12 个月时测量 eGFR(CKD-EPI),并在亚组(n=9)中通过评估时间强度曲线(TIC)下的面积来测量基线和 3 个月时的肾脏血流。测量谷胱甘肽过氧化物酶 3(GPx-3)活性作为氧化防御状态的生物标志物。
与常规治疗相比,联合使用维生素 E 和硒的 eGFR 变化时间最短(5.6[4.0-7.0] vs 8.9[6.8-10.9 个月];p=0.006)。与基线相比,TIC 下面积减少(38.52[22.41-90.49] vs 123[86.98-367.03]dB.s;p≤0.05和 347[175.88-654.92] vs 928.03[448.45-1683]dB.s;p≤0.05,分别),提示灌注率增加。在非白种人和白种人群中,12 个月时 eGFR 的变化比例在 GPx-3 活性高于队列中位数(360 U/L)的组中大于 GPx-3 活性低于队列中位数的组(225 U/L)(非白种人组为 19.1[12.5-25.7]% vs 6.5[-3.5-16.5]%,白种人组为 12.8[0.7-24]% vs 0.2[-6.1-6.5]%)。
在这些患有 2 型糖尿病和早期 CKD 的患者中,抗氧化治疗抑制了肾脏血流,eGFR 的升高与 GPx-3 活性直接相关。
糖尿病是全球导致终末期肾病的主要原因,与白种人相比,黑人和少数族裔更易发生终末期肾病。尽管常规治疗有获益,但风险差异可能与氧化应激有关。我们发现,在高危 2 型糖尿病患者中,当肾功能保持正常时,肾小球滤过率和肾脏血流受到抑制。硒-谷胱甘肽过氧化物酶-3(GPx-3)的辅助因子-补充常规治疗可改善肾脏灌注并增加肾小球滤过率,具体取决于宿主的抗氧化防御能力,由 GPx-3 活性决定。循环 GPx-3 活性值得进一步研究,作为早期糖尿病肾病可逆性血液动力学变化的新型生物标志物,以便更好地确定肾脏保护策略的靶向目标。